Vaccine makers race to update shots, in case
Vaccine makers are racing to update their COVID-19 shots against the newest coronavirus threat even before it’s clear a change is needed, just in case.
Experts doubt today’s shots will become useless but say it’s critical to see how fast companies could produce a reformulated dose and prove it works — because whatever happens with omicron, this newest mutant won’t be the last.
Omicron “is pulling the fire alarm. Whether it turns out to be a false alarm, it would be really good to know if we can actually do this — get a new vaccine rolled out and be ready,” said immunologist E. John Wherry of the University of Pennsylvania.
It’s too soon to know how vaccines will hold up against omicron. The first hints this week were mixed: Preliminary lab tests suggest two Pfizer doses may not prevent an omicron infection, but they could protect against severe illness. And a booster shot may rev up immunity enough to do both.
Better answers are expected in the coming weeks and regulators in the U.S. and other countries are keeping a close watch. The World Health Organization has appointed an independent scientific panel to advise on whether the shots need reformulating because of omicron or any other mutant.
But authorities haven’t laid out what would trigger such a drastic step: If vaccine immunity against serious illness drops, or if a new mutant merely spreads faster?
“This is not trivial,” BioNTech CEO Ugur Sahin, Pfizer’s vaccine partner, said shortly before omicron’s discovery. A company could apply to market a new formula “but what happens if another company makes another proposal with another variant? We don’t have an agreed strategy.”
It’s a tough decision — and the virus moves faster than science. Just this fall, the U.S. government’s vaccine advisers wondered why boosters weren’t retooled to target the extra-contagious delta variant — only to have the next scary mutant, omicron, be neither a delta descendant nor a very close cousin.
If vaccines do need tweaking, there’s still another question: Should there be a separate omicron booster or a combination shot? And if it’s a combo, should it target the original strain along with omicron, or the currently dominant delta variant plus omicron?
COVID-19 vaccines work by triggering production of antibodies that recognize and attack the spike protein that coats the coronavirus, and many are made with new technology flexible enough for easy updating. The Pfizer and Moderna vaccines are fastest to tweak, made with genetic instructions that tell the body to make harmless copies of the spike protein — and that messenger RNA can be swapped to match new mutations.
Pfizer expects to have an omicron-specific candidate ready for the Food and Drug Administration to consider in March, with some initial batches ready to ship around the same time, chief scientific officer Dr. Mikael Dolsten told The Associated Press.
Moderna is predicting 60 to 90 days to have an omicron-specific candidate ready for testing. Other manufacturers that make COVID-19 vaccines using different technology, including Johnson & Johnson, also are pursuing possible updates.
Pfizer and Moderna already have successfully brewed experimental doses to match delta and another variant named beta, shots that haven’t been needed but offered valuable practice.